A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases
Open Access
- 25 September 2014
- journal article
- research article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 16 (5), 1-8
- https://doi.org/10.1186/s13075-014-0435-y
Abstract
We performed a meta-analysis to investigate the risk of deep vein thrombosis (DVT) and/or pulmonary embolisms (PEs) in patients with inflammatory arthritis, vasculitis and connective tissue diseases (CTDs) (systemic lupus erythematosus (SLE), Sjögren's syndrome, inflammatory myositis and systemic sclerosis (SSc)). PubMed, Embase, the Cochrane databases and MEDLINE were searched to identify full-text English-language publications about adult patients with rheumatologic inflammatory diseases and venous thromboembolisms (VTEs). Data regarding rates of DVTs and PEs were extracted. Using random-effects models, pooled estimates for VTEs in individual and pooled diseases were compared with matched populations where possible. Studies were excluded if VTEs were described in the setting of pregnancy, postoperative outcomes or solely antiphospholipid antibody syndrome. Most of the 5,206 studies were excluded because they did not state the rate or incidence of VTEs. In total, 25 studies remained for analysis. Ten studies that included rheumatoid arthritis comprised an aggregate of 5,273,942 patients and 891,530,181 controls with a cumulative VTE incidence of 2.18% (95% confidence interval (CI): 1.82% to 2.54%) and an odds ratio of 2.23 (95% CI: 2.02 to 2.47) compared to age- and sex-matched populations. Ten studies comprised an aggregate of 54,697 SLE patients with a cumulative VTE incidence of 7.29% (95% CI: 5.82% to 8.75%). Four Sjögren's syndrome studies comprising an aggregate of 25,100 patients demonstrated a cumulative VTE incidence of 2.18% (95% CI: 0.79% to 3.57%). Four studies of inflammatory myositis comprising an aggregate of 8,245 patients yielded a cumulative VTE incidence of 4.03% (95% CI: 2.38% to 5.67%). The SSc- and antineutrophil cytoplasmic antibody vasculitis–related cumulative VTE rates (four studies each) were 3.13% and 7.97%, respectively. The inflammatory rheumatologic diseases studied were all associated with high rates of VTEs—more than three times higher than in the general population.Keywords
This publication has 35 references indexed in Scilit:
- Incidence of and Mortality from Venous Thromboembolism in a Real-world Population: The Q-VTE Study CohortThe American Journal of Medicine, 2013
- Noncardiac vascular disease in rheumatoid arthritis: Increase in venous thromboembolic events?Arthritis & Rheumatism, 2011
- Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage studyBMC Medicine, 2011
- Factors predictive of thrombotic events in LUMINA, a multi-ethnic cohort of SLE patients (LXXII)Rheumatology, 2010
- Thrombosis in Systemic Lupus Erythematosus and Other Autoimmune Diseases of Recent OnsetThe Journal of Rheumatology, 2009
- Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohortAnnals Of The Rheumatic Diseases, 2008
- Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patientsArthritis & Rheumatism, 2005
- The Epidemiology of Venous ThromboembolismCirculation, 2003
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986